EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Kyunghye Bang iD, Andrea Casadei-Gardini, Changhoon Yoo iD, Massimo Iavarone, Min-Hee Ryu, Sook Ryun Park, Hyung-Don Kim, Young-In Yoon, Dong-Hwan Jung, Gil-Chun Park, Chul-Soo Ahn, Deok-Bog Moon und 9 weitere

Cancer Medicine · 2023-02 · 12 (3) · 2572-2579

DOI: 10.1002/cam4.5123 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 05.08.2022. Verfasst von Kyunghye Bang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence remain unclear. We investigated the efficacy and safety of lenvatinib in patients with post‐LT HCC recurrence.

Methods

This multinational, multicenter, retrospective study included 45 patients with recurrent HCC after LT who received lenvatinib at six institutions in three countries (Korea, Italy, and Hong Kong) from June 2017 to October 2021.

Results

At the time of lenvatinib initiation, 95.6% ( n = 43) of patients had Child–Pugh A status, and 35 (77.8%) and 10 (22.2%) participants were classified as having albumin–bilirubin (ALBI) grades 1 and 2, respectively. The objective response rate was 20.0%. With a median follow‐up duration of 12.9 months (95% confidence interval [CI]: 11.2–14.7), the median progression‐free survival and overall survival (OS) were 7.6 (95% CI: 5.3–9.8) months, and 14.5 (95% CI: 0.8–28.2) months, respectively. Patients with ALBI grade 1 showed significantly better OS (52.3 months, [95% CI: not assessable]) than patients with ALBI grade 2 (11.1 months [95% CI: 0.0–30.4 months], p = 0.003). The most common adverse events were hypertension ( n = 25, 55.6%), fatigue ( n = 17, 37.8%), and anorexia ( n = 14, 31.1%).

Conclusion

Lenvatinib showed consistent efficacy and toxicity profiles in patients with post‐LT HCC recurrence that were comparable to those reported from previous studies among non‐LT HCC patients. The baseline ALBI grade correlated with better OS in post‐LT lenvatinib‐treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationHumansRetrospective StudiesSerum AlbuminBiomarkers, TumorBilirubinPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

Albumin-bilirubin gradechemotherapyhepatocellular carcinomalenvatinibliver transplantation

Substanzen

Serum AlbuminBiomarkers, TumorBilirubinlenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Division of Hemato-Oncology, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Republic of Korea.
  • Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Hepatology and Gastro-Enterology Unit, ASST Ospedale Niguarda, Milan, Italy.

ORCID-Profile: Kyunghye Bang, Changhoon Yoo

Zitieren

APA

Bang, K., Casadei-Gardini, A., Yoo, C., Iavarone, M., Ryu, M. H., Park, S. R., Kim, H. D., Yoon, Y. I., Jung, D. H., Park, G. C., Ahn, C. S., Moon, D. B., Hwang, S., Kim, K. H., Song, G. W., Mazzarelli, C., Alimenti, E., Chan, S. L., De Giorgio, M., …, & Lee, S. G. (2023). Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Medicine, 12(3), 2572-2579. https://doi.org/10.1002/cam4.5123

Vancouver

Bang K, Casadei-Gardini A, Yoo C, Iavarone M, Ryu MH, Park SR, et al. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Medicine. 2023;12(3):2572-2579. doi:10.1002/cam4.5123

BibTeX
@article{Bang2023,
  author = {Bang, Kyunghye and Casadei-Gardini, Andrea and Yoo, Changhoon and Iavarone, Massimo and Ryu, Min-Hee and Park, Sook Ryun and Kim, Hyung-Don and Yoon, Young-In and Jung, Dong-Hwan and Park, Gil-Chun and Ahn, Chul-Soo and Moon, Deok-Bog and Hwang, Shin and Kim, Ki-Hun and Song, Gi-Won and Mazzarelli, Chiara and Alimenti, Eleonora and Chan, Stephen L and De Giorgio, Massimo and Ryoo, Baek-Yeol and Lee, Sung-Gyu},
  title = {Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {2572--2579},
  doi = {10.1002/cam4.5123}
}
Kostenlos starten →